Xichun Hu

Shanghai Medical College of Fudan University — China

Medicine · Health Sciences

36h-index4.5kcitations260works3.92yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Treatment and Pharmacology(82), Advanced Breast Cancer Therapies(66), HER2/EGFR in Cancer Research(59), Breast Cancer Treatment Studies(39), Monoclonal and Polyclonal Antibodies Research(18)

Publications259 total

The methyltransferase-like proteins as core regulators of nucleic acid modifications and post-translation modification of proteins in disease pathogenesis and therapeutic implications
Biomarker Research·2025Open Access
Efficacy and safety of ARX788 for individuals with HER2-positive breast cancer and brain metastases (ACE-Breast-06): a single-arm, phase 2 trial in China
EClinicalMedicine·2025Open Access
Clinical and genomic characteristics of HER2-ultralow breast cancer and implications for T-DXd therapy
Precision Clinical Medicine·2025· 1 citedOpen Access
Safety and tolerability of bireociclib for the treatment of advanced solid tumors as monotherapy and in combination with endocrine therapy: a multicenter, open-label, phase 1 clinical trial
BMC Medicine·2025Open Access
Abstract P2-03-16: Prevalence of PIK3CA/AKT1/PTEN and other genomic alterations in primary and recurrent tumor tissue: exploratory analysis from the Phase 3 CAPItello-291 clinical trial
Clinical Cancer Research·2025
Abstract P5-05-02: Pharmacokinetic profile and preliminary efficacy of GQ1001, a next generation HER2-targeting ADC, combined with pyrotinib in pretreated patients with HER2-positive metastatic breast cancer: A phase 1b clinical trial
Clinical Cancer Research·2025
Abstract PS2-01: Dalpiciclib versus placebo in combination with letrozole or anastrozole as first-line treatment for women with HR+/HER2- advanced breast cancer: prespecified final analysis of progression-free survival of the phase 3 DAWNA-2 trial
Clinical Cancer Research·2025
Abstract P2-03-19: Capivasertib-fulvestrant for patients w/ HR-pos/HER2-negative advanced breast cancer who had relapsed or progressed during or after aromatase inhibitor treatment: exploratory analysis of PTEN deficiency by IHC from phase III CAPItello-291 trial
Clinical Cancer Research·2025· 1 cited
Vepdegestrant, a PROTAC estrogen receptor (ER) degrader, vs fulvestrant in ER-positive/human epidermal growth factor receptor 2 (HER2)–negative advanced breast cancer: Results of the global, randomized, phase 3 VERITAC-2 study.
Journal of Clinical Oncology·2025· 7 cited
Vepdegestrant, a PROTAC Estrogen Receptor Degrader, in Advanced Breast Cancer
New England Journal of Medicine·2025· 57 cited
IMM2510, an anti-PD-L1/VEGF bispecific antibody fusion protein, in patients with R/R STS: A phase Ib expansion study.
Journal of Clinical Oncology·2025
Granisetron transdermal delivery system for nausea and vomiting prophylaxis in HER2-positive metastatic breast cancer patients receiving pyrotinib and capecitabine: A single-arm phase II study.
Journal of Clinical Oncology·2025
Clinical and genomic characteristics of HER2-IHC 0 (membrane staining +) breast cancer and implications for T-DXd therapy.
Journal of Clinical Oncology·2025
A phase II clinical study of adebrelimab and bevacizumab combined with cisplatin/carboplatin in triple-negative breast cancer patients with brain metastases.
Journal of Clinical Oncology·2025
PD-1 blockade in combination with bevacizumab and nab-paclitaxel for second-line treatment in cancer of unknown primary (Fudan CUP-002): A prospective, single-arm phase II study.
Journal of Clinical Oncology·2025
Capivasertib plus fulvestrant in patients with HR-positive/HER2-negative advanced breast cancer: phase 3 CAPItello-291 study extended Chinese cohort
Nature Communications·2025· 9 citedOpen Access
8MW0511, a novel, long-acting granulocyte-colony stimulating factor fusion protein for the prevention of chemotherapy-induced neutropenia: final results from the phase III clinical trial
Breast Cancer Research·2025Open Access
Transcriptomic splicing analysis reveals a gene-independent form of TE reactivation in tumors representing unrecognized source of oncogenes and neoantigens
2025
A phase I dose-escalation and expansion study of RMX1002, a selective E-type prostanoid receptor 4 antagonist, as monotherapy and in combination with anti-PD-1 antibody in advanced solid tumors
Investigational New Drugs·2025· 1 citedOpen Access
ACE-Breast-02: a randomized phase III trial of ARX788 versus lapatinib plus capecitabine for HER2-positive advanced breast cancer
Signal Transduction and Targeted Therapy·2025· 21 citedOpen Access
page 1 of 13Next →

Frequent Co-authors

Biyun Wang(18), Zhonghua Tao(12), Jian Zhang(9), Zhonghua Wang(8), Jun Cao(8), Zefei Jiang(7), Zhongsheng Tong(7), Leiping Wang(7), Zhimin Shao(7), Yueyin Pan(6), Binghe Xu(6), Tao Sun(6), Min Yan(6), Yannan Zhao(6), Xiaojia Wang(5), Jifeng Feng(5), Shusen Wang(5), Yuee Teng(5), Zhonghua Wang(5), Qingyuan Zhang(4)